<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704429</url>
  </required_header>
  <id_info>
    <org_study_id>PRN1008-005</org_study_id>
    <nct_id>NCT02704429</nct_id>
  </id_info>
  <brief_title>A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris</brief_title>
  <official_title>An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Principia Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Principia Biopharma Australia Pty Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Principia Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus
      vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy,
      and with conventional immunosuppressive &quot;rescue treatment&quot;, if indicated. The duration of
      therapy will be 12 weeks, followed by 12 weeks of follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      To evaluate the safety of PRN1008 in patients with pemphigus vulgaris (PV) To evaluate the
      clinical activity of PRN1008 in patients with PV, per criteria in the European Academy of
      Dermatology and Venereology (EADV) 2014 Pemphigus S2 Guideline (Hertl et al. 2015)

      Secondary Objectives To evaluate the pharmacokinetics (PK) and the pharmacodynamics (PD) of
      multiple doses of PRN1008 in patients with PV To evaluate the relationship of PK and PD to
      each other and to efficacy and safety in this patient population
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events at 12 weeks</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAEs), including clinically significant changes in physical examination, laboratory tests, and vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Control of disease activity at 4 weeks</measure>
    <time_frame>4 weeks treatment</time_frame>
    <description>The proportion of subjects who are able to achieve control of disease activity (CDA) within 4 weeks of starting PRN1008 treatment without the need for doses of prednisone or prednisolone &gt;0.5 mg/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to control of disease activity (CDA)</measure>
    <time_frame>12 week treatment; 12 week follow up</time_frame>
    <description>Time to control of disease activity (CDA) as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to end of consolidation phase</measure>
    <time_frame>12 week treatment; 12 week follow up</time_frame>
    <description>Time to end of consolidation phase as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete remission</measure>
    <time_frame>12 week treatment; 12 week follow up</time_frame>
    <description>Time to complete remission as defined in European Academy of Dermatology2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse after PRN1008 treatment discontinuation</measure>
    <time_frame>12 week treatment; 12 week follow up</time_frame>
    <description>Time to relapse after PRN1008 treatment discontinuation as defined in European Academy of Dermatology and Venereology (EADV) 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pemphigus Vulgaris</condition>
  <arm_group>
    <arm_group_label>PRN1008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label PRN1008, 12 weeks; 12 week follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRN1008</intervention_name>
    <description>PRN1008, oral dose, 12 weeks</description>
    <arm_group_label>PRN1008</arm_group_label>
    <other_name>BTK inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV
             (PDAI 8 to 45) that are either:

               -  newly diagnosed patients (i.e. naïve to an effective induction treatment regimen)
                  for whom an initial period of PRN1008 monotherapy is judged clinically
                  acceptable, or

               -  relapsing patients, for whom an initial period of PRN1008 monotherapy, or
                  combination therapy with any of low dose corticosteroid (≤ 10 mg/day),
                  azathioprine, mycophenolate mofetil, sulfasalazine and dapsone, is judged
                  clinically acceptable, provided cessation of azathioprine, mycophenolate mofetil,
                  sulfasalazine, and dapsone within two to four weeks is anticipated

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  A history of malignancy of any type, other than surgically excised non-melanoma skin
             cancers or in situ cervical cancer within 5 years before the day of dosing

          -  Use of immunologic response modifiers with the following periods prior to Day 1: 1
             week: cyclophosphamide; 4 weeks: Kinaret (anakinra) and Enbrel (etanercept); 12 weeks:
             Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept),
             Actemra (tocilizumab), Cimzia (certolizumab), Cosentyx (secukinumab), intravenous
             immunoglobulin, plasmapheresis; 6 months: Rituxan/MabThera (rituximab), ofatumumab,
             any other anti-CD20 antibody

          -  Use of &gt;10 mg per day of oral prednisolone for more than 1 week within 4 weeks prior
             to Day 1 (inhaled and mucosal [for symptomatic treatment of oral lesions]
             corticosteroids are allowed)

          -  Has received any investigational drug (or is currently using an investigational
             device) within the 30 days before receiving the first dose of study medication, or at
             least 5 times the respective elimination half-life time (whichever is longer)

          -  Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1

          -  History of solid organ transplant

          -  Positive for screening for HIV, hepatitis B (surface and core antibodies unrelated to
             vaccination), or hepatitis C (anti-HCV antibody confirmed with Hep C RNA)

          -  History of active or latent tuberculosis (TB) infection (subjects must also test
             negative using the QuantiFERON® test to be eligible for the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven G Gourlay, MBBS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Principia Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven G Gourlay, MBBS PhD</last_name>
    <phone>650-416-7700</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert C Quesenberry, BS PMP CRP</last_name>
    <phone>650-416-7700</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Premier Specialists</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Peras, RN</last_name>
      <phone>+61295985800</phone>
      <email>murrell.patients@ori.org.au</email>
    </contact>
    <investigator>
      <last_name>Dedee F. Murrell, BMBCh FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Robinson</last_name>
      <phone>+61 3 9654 2426</phone>
      <email>Carol.Robinson@sinclairdermatology.com.au</email>
    </contact>
    <investigator>
      <last_name>Rodney D Sinclair, MBBS MD FACD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne, Dermatology Office</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Phemister, RN</last_name>
      <phone>+61 3 9342 4531</phone>
      <email>Annette.phemister@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>George A Varigos, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmina Knezevic</last_name>
      <phone>﻿﻿+385915460138</phone>
      <email>knezevic.jasmina@kbo.hr</email>
    </contact>
    <investigator>
      <last_name>Marija Sola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinichki Bolnicki Centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Vrcic, MD</last_name>
      <phone>+38516051935</phone>
      <email>tanja.vrcic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Branka Marinovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Siene-Saint Denis</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Caux</last_name>
      <phone>﻿﻿+33148955189</phone>
    </contact>
    <investigator>
      <last_name>Frederic Caux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Stiti</last_name>
      <phone>+33243434351</phone>
      <email>samir.stiti@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Joly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioánnina</city>
        <state>Ioannina</state>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrisanthi Tziortzioti</last_name>
      <phone>﻿﻿+306949082918</phone>
      <email>sissitziortzioti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>George Gaitanis</last_name>
      <phone>﻿﻿+306974508561</phone>
      <email>ggaitan@cc.uoi.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Ioannis Bassukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeliki-Viktoria Roussaki-Schulze, MD</last_name>
      <email>roussaki@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Angeliki-Viktoria Roussaki-Schulze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Venereal and Skin Diseases A.Syggros</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioanna Kalkounou</last_name>
      <phone>﻿﻿+306945860027</phone>
      <email>ikalkounou@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Panagiotis Stavropoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aikaterini Kyriakou</last_name>
      <phone>+302313323291</phone>
      <email>docmouli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aikaterini Patsatsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaron Ben-Mordechai</last_name>
      <phone>﻿﻿+97236666666</phone>
      <email>jaronbm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Baum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dvora Cohen</last_name>
      <phone>+97236973768</phone>
      <email>dvoray@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tal Zeeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

